Evaxion A/S
Evaxion utilizes its AI-Immunology™ platform to challenge and improve standardized treatments. In oncology, they create personalized therapies, tailoring treatment to the individual. For infectious diseases, they design next-generation vaccines to address unmet medical needs. Their AI platform accelerates vaccine target discovery, design, and development.
Registre Officiel
Dernière vérification: 1/2/2026
Analyse Qualité IA
Détails du Score de Confiance
Liens Rapides
Points forts du site
🌟 Entreprises similaires de confiance
Context Therapeutics Inc.
Context Therapeutics is dedicated to advancing the treatment of solid tumors through the development of next-generation T cell engaging (TCE) bispecific antibody therapies. Their innovative pipeline features clinical-stage bispecific therapeutics designed to harness the immune system for targeted cancer eradication. The company focuses on innovative immunotherapeutic solutions, transforming cancer care and improving outcomes for patients.
AGENUS INC
Agenus is a biotechnology company focused on developing and commercializing immuno-oncology therapies. Their key products include botensilimab and balstilimab, which are in clinical trials for various cancers. The company is positioned as an innovator in the development of next-generation immunotherapies.
Quanterix Corp
Quanterix is revolutionizing healthcare through ultra-sensitive biomarker detection. They empower researchers with Simoa® technology, offering precision instruments, a wide range of assay kits, and custom assay development services. Their technology enables breakthroughs in disease understanding and management, particularly in neurology, oncology, and immunology. Quanterix is setting a new gold standard for biomarker detection.